# HAIC Plus H101 vs HAIC Alone for Unresectable HCC at BCLC A-B

Source: https://onco.cc/trials/nct03780049/  
OnCo record `nct03780049` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of H101 oncolytic adenovirus in Hepatocellular carcinoma, run by Sun Yat-sen University, with a status the registry has not verified recently.

## Summary

HAIC Plus H101 vs HAIC Alone for Unresectable HCC at BCLC A-B is a phase 3 interventional study registered as NCT03780049 by Sun Yat-sen University, with 304 participants planned, started 2018-10-01 and due to reach its primary completion in 2023-10-01. Interventions recorded: HAIC of FOLFOX, H101, Placebos. Conditions recorded: Hepatocellular Carcinoma.

Linked to the drug H101 oncolytic adenovirus because the registry names it among its interventions and Hepatocellular carcinoma among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT03780049
- Phase: 3
- Setting: Hepatic Artery Infusion Chemotherapy Plus Recombinant Human Type-5 Adenovirus vs Hepatic Artery Infusion Chemotherapy Alone for Unresectable Hepatocellular Carcinoma at Barcelona Clinic Liver Cancer A-B Stage
- Sponsor: Sun Yat-sen University
- Enrolled: 304

## Sources

- ClinicalTrials.gov NCT03780049: https://clinicaltrials.gov/study/NCT03780049

## Connected records

- cancers: [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/)
- drugs: [H101 oncolytic adenovirus](https://onco.cc/drugs/h101-oncolytic-adenovirus/)

---
JSON: https://onco.cc/api/v1/entities/nct03780049.json